 - To determine whether pre-treatment levels of biomarkers e.g., neuregulin, IGF-1, cardiotrophin-1, IL-6, VEGF, hepatocyte growth factor, and heparin binding EGF in these patients, correlate with relative risk of developing NCI grade 1 cardiotoxicity to this regimen. Primary study 